Clinical assessment of antisecretory drugs in man.

Boyd, E J; Wormsley, K. G.

doi:10.1111/j.1365-2125.1982.tb04929.x

Cited by 4 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inhibition of nocturnal gastric secretion by nighttime administration of antisecretory drugs is also the basis for maintenance of ulcer remission. Newly developed gastric antisecretory drugs to be used for the treatment of duodenal ulcer disease are therefore routinely tested for their ability to inhibit nocturnal gastric secretion (4).…”

mentioning

confidence: 99%

Nocturnal Gastric Secretion in Duodenal Ulcer Patients and Healthy Controls. Ranges and Reproducibility

Boyd

Wormsley²

1992

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

The nocturnal gastric acid secretion of 22 male duodenal ulcer patients was compared with that of 47 healthy male volunteers. Median nocturnal acid output was greater in duodenal ulcer patients (55 mmol versus 33 mmol 10 h-1; p = 0.013), but there was almost complete overlap of the ranges. Five duodenal ulcer patients and three volunteers had nocturnal outputs of acid previously considered to be pathognomonic of the Zollinger-Ellison syndrome in the absence of other evidence of a gastrinoma. Nineteen healthy volunteers underwent a repeat study to assess the reproducibility of nocturnal gastric acid output. Median intraindividual variability (+/- distribution-free 95% confidence limits) was 23% (-34% to +72%). Studies of nocturnal gastric secretion are of no diagnostic value, and their variability should be taken into consideration when evaluating gastric antisecretory drugs.

show abstract

mentioning

confidence: 99%

Nocturnal Gastric Secretion in Duodenal Ulcer Patients and Healthy Controls. Ranges and Reproducibility

Boyd

Wormsley²

1992

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

The Alimentary System

Maxwell

1984

Principles of Paediatric Pharmacology

View full text Add to dashboard Cite

Effects of FCE 20700, a new PGE2 derivative, on gastric acid secretion and cytoprotective processes in man

Caldara

Carbone

Masci

et al. 1987

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The pharmacodynamic effects of FCE20700, a new PGE2 derivative, have been investigated in 6 healthy volunteers given single intragastric (i.g.) and intraduodenal (i.d.) doses of 1 and 2 mg and placebo, according to a double-blind, within-subjects design. For 30-270 min following i.g. administration the effect of FCE20700 on peptone-stimulated gastric acid secretion (AS) was assessed by i.g. titration, and serum gastrin (G) levels were also determined. For the same period after i.d. dosing the effect of the compound on pentagastrin-stimulated AS and on mucoproteins and bicarbonate content in the gastric juice was measured. Blood pressure (BP), heart rate and possible side-effects were monitored. Following i.g. administration there was a moderate, dose-related, significant inhibition of AS; significant inhibition of G levels was observed only after the highest dose. After i.d. administration there was a very modest though dose-related and significant inhibition of AS; a brief maximal increase in mucoproteins and in bicarbonate levels was apparent after the 1 mg dose. After i.d. but not after i.g. administration of 2 mg there was a modest but significant decrease in BP. No side-effects of clinical relevance were reported. The results appear to suggest a major activity of FCE20700 on cytoprotection rather than in inhibiting gastric acid secretion. The observed change in BP may indicate that after i.d. administration there will be some systemic effects of FCE20700.

show abstract

Clinical assessment of antisecretory drugs in man.

Cited by 4 publications

References 45 publications

Nocturnal Gastric Secretion in Duodenal Ulcer Patients and Healthy Controls. Ranges and Reproducibility

Nocturnal Gastric Secretion in Duodenal Ulcer Patients and Healthy Controls. Ranges and Reproducibility

The Alimentary System

Effects of FCE 20700, a new PGE2 derivative, on gastric acid secretion and cytoprotective processes in man

Contact Info

Product

Resources

About